戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and additional variables such as exposure to cranial irradiation.
2 and (3) understanding approach and timing of cranial irradiation.
3 oncurrent RT, RT technique, and prophylactic cranial irradiation.
4 protect against adverse cognitive effects of cranial irradiation.
5 vant chemotherapy alone or chemotherapy with cranial irradiation.
6                   All underwent prophylactic cranial irradiation.
7 in metastases, and 8% underwent prophylactic cranial irradiation.
8 gnitive decline in cancer patients receiving cranial irradiation.
9 t of patients with brain tumors had received cranial irradiation.
10 except those with low-risk disease, received cranial irradiation.
11 sk-adapted chemotherapy without prophylactic cranial irradiation.
12 l learning and memory impairments induced by cranial irradiation.
13 at may potentially benefit from prophylactic cranial irradiation.
14    Complete responders received prophylactic cranial irradiation.
15 S relapse after a short initial remission or cranial irradiation.
16 f deleterious neurocognitive consequences of cranial irradiation.
17  or adaptive deficits if they do not undergo cranial irradiation.
18 of adding RT to chemotherapy or prophylactic cranial irradiation.
19 inflammation and augments neurogenesis after cranial irradiation.
20 d cyclophosphamide, 58 of whom also received cranial irradiation.
21 chemotherapy drugs, intrathecal therapy, and cranial irradiation.
22 justify future trials including prophylactic cranial irradiation.
23 s associated with intensive chemotherapy and cranial irradiation.
24 y when treated with 23.4 Gy instead of 36 Gy cranial irradiation.
25 r irradiation, we investigated the impact of cranial irradiation (1 and 10 Gy) on a range of micromor
26 T-cell patients who received chemotherapy or cranial irradiation (12 Gy) to prevent overt leukemia in
27                                 Prophylactic cranial irradiation (12-18 Gy) is given to 2-20% of pati
28 toposide/cisplatin, followed by prophylactic cranial irradiation (30 Gy/15 fractions) if they had a c
29                                              Cranial irradiation alone rarely results in long-term di
30 y and provide the basis for studies omitting cranial irradiation altogether.
31                               Younger age at cranial irradiation and higher dosage were associated wi
32 ation, hippocampal avoidance in prophylactic cranial irradiation and whole brain radiotherapy, and th
33 n = 190, including 99 patients who underwent cranial irradiation), and radiation alone (n = 22).
34  ototoxic cancer treatment (platinum agents, cranial irradiation, and/or brain surgery) require a bas
35 lude patients with brain cancer treated with cranial irradiation (approximately 70% develop severe or
36                   Cancer patients undergoing cranial irradiation are at risk of developing neurocogni
37 hemotherapy will, in all likelihood, replace cranial irradiation as subclinical central nervous syste
38 ession of adult hippocampal neurogenesis via cranial irradiation before drug-taking significantly inc
39 atients who have previously received maximal cranial irradiation but suffer an intracranial recurrenc
40 ive risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treat
41                                      Because cranial irradiation can cause many acute and late compli
42                                              Cranial irradiation can lead to long-lasting cognitive i
43 n female sex and cognitive dysfunction after cranial irradiation, cardiovascular outcomes, obesity, r
44      Endocrine deficiencies are common after cranial irradiation, chemotherapy and specific tumors.
45 vel procedure for administering fractionated cranial irradiation (CI) and investigated the incidence
46                                    High-dose cranial irradiation (CI) during early developmental stag
47 ancers who received high doses (40-60 Gy) of cranial irradiation (CI) have increased risks of develop
48  clinical trial to test whether prophylactic cranial irradiation could be omitted from treatment in a
49 d expression profiling of RIGs arising after cranial irradiation for MB (n = 23) and ALL (n = 9).
50 m lymphoma and those undergoing prophylactic cranial irradiation for systemic malignancies.
51                    For patients subjected to cranial irradiation for the control of CNS malignancy, p
52                                              Cranial irradiation for the treatment of brain cancer el
53 en reported in patients after treatment with cranial irradiation for various primary malignancies suc
54 ern using hippocampal avoidance-prophylactic cranial irradiation (HA-PCI) in patients with small-cell
55                                 Prophylactic cranial irradiation has been a standard treatment in chi
56 esulting in shortened survival, prophylactic cranial irradiation has been proposed in both small-cell
57 ) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disea
58 ce imaging surveillance without prophylactic cranial irradiation, hippocampal avoidance in prophylact
59                                              Cranial irradiation impacted neurocognitive outcomes, es
60  that reason, T-ALL patients usually receive cranial irradiation in addition to intensified intrathec
61 ents are a feared consequence of therapeutic cranial irradiation in children as well as adults.
62 ) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a
63                                 Prophylactic cranial irradiation in near or complete responders to in
64 ied the use of combination chemotherapy plus cranial irradiation in newly diagnosed patients with PCN
65 andomised controlled studies of prophylactic cranial irradiation in oncology patients as well as stud
66 t chemotherapy with and without prophylactic cranial irradiation in patients who undergo complete res
67 al designs of ongoing trials of prophylactic cranial irradiation in stage III NSCLC have taken this i
68 need to eliminate relapse without the use of cranial irradiation in very high-risk patients.
69 um-etoposide every 3 weeks plus prophylactic cranial irradiation (investigator's discretion) in the p
70 side every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion).
71 ing from hippocampal cytotoxicity induced by cranial irradiation (IR) present a challenge in the trea
72         High-dose methotrexate combined with cranial irradiation is an effective therapeutic approach
73                        Although prophylactic cranial irradiation is potentially associated with neuro
74                                              Cranial irradiation is the main therapeutic treatment fo
75                                        Prior cranial irradiation is the most common cause for ocular
76                                              Cranial irradiation is used routinely for the treatment
77                                              Cranial irradiation is widely used in cancer therapy, bu
78  frequent result of cancer therapy involving cranial irradiation, leaving patients with marked memory
79 ons were similar in OE and KO mice following cranial irradiation, molecular analyses suggested that t
80  cerebellar tumours but who received neither cranial irradiation nor methotrexate chemotherapy.
81 a meta-analysis have shown that prophylactic cranial irradiation not only reduces the incidence of br
82 t-derived microglia engraftment, rather than cranial irradiation or BMT alone, was responsible for th
83  functions have undergone surgery as well as cranial irradiation or methotrexate treatment.
84 kout (-/-) and wild-type mice received 10 Gy cranial irradiation or sham-treatment.
85  weight (OR, 0.97), attained age (OR, 0.98), cranial irradiation (OR, 2.07), and abdominal irradiatio
86 .97), current smoking status (OR, 1.48), and cranial irradiation (OR, 2.11).
87 e considered for treatment with prophylactic cranial irradiation, owing to the high frequency of brai
88 ected to a clinically relevant, fractionated cranial irradiation paradigm were given multiple injecti
89  radiotherapy (TRT) followed by prophylactic cranial irradiation (PCI) for responsive disease.
90                                 Prophylactic cranial irradiation (PCI) has been shown to provide surv
91 y was conducted to determine if prophylactic cranial irradiation (PCI) improves survival in locally a
92 ial hypothesized that HA during prophylactic cranial irradiation (PCI) in patients with small cell lu
93 oracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in l
94      To investigate the role of prophylactic cranial irradiation (PCI) within a trimodality protocol
95 latin and etoposide (PE), early prophylactic cranial irradiation (PCI), and high-dose twice-daily tho
96 th limited disease) to standard prophylactic cranial irradiation (PCI; 25 Gy in 10 fractions) or HA-P
97 ; strata were tumor-node group, prophylactic cranial irradiation policy, and region.
98                                 Prophylactic cranial irradiation prolongs survival in patients with l
99 al hypothyroidism including ischemic injury, cranial irradiation, psychiatric conditions, or medical
100 t chemotherapy, with or without prophylactic cranial irradiation, relative to no adjuvant therapy for
101                                              Cranial irradiation remains a frontline treatment for th
102 tive cancer treatment regimens often require cranial irradiation, resulting in lifelong neurocognitiv
103 re older and those treated with reduced-dose cranial irradiation (RRT) of 23.4 Gy.
104  after treatment with a combination of 10 Gy cranial irradiation (RT) and anti-PD-1 checkpoint blocka
105 cic radiotherapy in addition to prophylactic cranial irradiation should be considered for all patient
106 agnosis and those who received standard-dose cranial irradiation (SRT) of 36 Gy would have a lower pe
107 st decade, standard therapy has evolved from cranial irradiation to high dose methotrexate-based regi
108                                              Cranial irradiation used to control brain malignancies i
109 that hNSC-derived EV resolves RICD following cranial irradiation using an immunocompromised rodent mo
110                   Stratification by previous cranial irradiation was added later as a protocol amendm
111                                However, when cranial irradiation was blocked by lead shield, and micr
112  previously would have received prophylactic cranial irradiation was compared with that of 56 histori
113 in-directed radiation including prophylactic cranial irradiation was not permitted.
114                                              Cranial irradiation was reserved for patients with highe
115                                              Cranial irradiation was reserved for the 12% of patients
116 treatment on Total X therapy, and the use of cranial irradiation, which was dose-dependent.
117                                    Following cranial irradiation, widespread senescence in the brain
118 ature neurons was strongly reduced following cranial irradiation with (137)Cs, this treatment did not
119 ley rats received a single 18 Gy fraction of cranial irradiation with protons at 1 Gy/s (CV), 60 Gy/s
120 I or II vs. III) and receipt of prophylactic cranial irradiation (yes vs. no).

 
Page Top